Dr. Sima Porten is an Associate Professor at UCSF in the Department of Urology and was recently named the Chief of the Division of Urologic Oncology. Her clinical and research expertise is in the diagnosis and management of bladder and upper tract urothelial cancer. In studying the biologic basis of urothelial carcinoma using genomic techniques, Dr. Porten hopes to develop new tests and novel therapeutics to bring personalized medicine to patients with bladder cancer.

Maxwell V. Meng, MD is Professor and Vice-chair of Urology at the University of California San Francisco (UCSF). He has been at UCSF for over 30 years and has treated those with urologic cancers since 2003. His focus remains on providing innovative and compassionate care for patients with testis, kidney, and bladder cancer and he is actively engaged in clinically-relevant research and teaching the next generation of urologists. He has been fortunate to work with the outstanding team at UCSF, the San Francisco community, and patients and their advocates to advance the treatment of patients with cancers.

Matthew Gubens, MD, MS, FASCO is Professor of Medicine at the University of California, San Francisco where he practices as a medical oncologist specializing in lung cancer, mesothelioma, and thymic malignancies with a particular interest in new immnunotherapies and targeted therapies. He serves as Medical Director of Thoracic Medical Oncology and as Chair of the UCSF Cancer Center Protocol Review and Monitoring Committee which oversees review of all clinical cancer research at the institution. He serves on the panel of the National Comprehensive Cancer Network guidelines that Medicare and other insurers use to support coverage of treatment for lung cancer and other thoracic cancers. He holds a BA from Yale, a MS from the Harvard School of Public Health, and an MD from Stanford Medical School. He trained at UCSF for internal medicine and at Stanford for medical oncology before joining the faculty at UCSF In 2011.